Pennsylvania ends Medicaid coverage for GLP-1 obesity drugs
Pennsylvania ended Medicaid coverage for GLP-1 drugs for adult obesity on Jan. 1, 2026, after state spending on the medications jumped in 2025.
Pennsylvania ended Medicaid coverage for GLP-1s like Ozempic to treat obesity in adults older than 21 starting Jan. 1, 2026. The decision was largely driven by financial considerations, with Pennsylvania’s Medicaid spending on GLP-1s soaring to an estimated $1.3 billion in 2025.